Premium
P1‐257: Once‐daily memantine treatment improves cognition and functional communication in patients with moderate to severe AD: Results of a 16‐week, single‐arm, open‐label trial
Author(s) -
Schulz Joerg,
Rainer Michael,
Klünemann HansHermann,
Kurz Alexander,
Wolf Stefanie,
Sternberg Kati,
Tennigkeit Frank
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.265
Subject(s) - memantine , tolerability , clinical endpoint , medicine , placebo , adverse effect , population , clinical trial , dementia , disease , alternative medicine , environmental health , pathology
controlled trials and 495 controlled clinical trials in dementia and cognitive impairment. As at 1st April 2009 this includes all completed, ongoing and aborted studies identified by sensitive monthly searches. As well as citations, the displayed data include: study design/blinding, participants and health condition, intervention and dosage, number of participants, outcomes, date of study, website links and related Cochrane reviews/protocols. Conclusions: ALOIS is an online study-based register which will supply review authors, investigators, researchers and other stakeholders with a unique and upto-date source of all published and unpublished studies in the area of dementia treatment/prevention and cognitive enhancement. The site will be launched online in June 2009. Funded by Alzheimer’s Association, USA.